One of the hottest areas in medicine today is drug delivery. Even the most beneficial drugs in the world are of little value if they cannot be successfully introduced when and where they are needed. Any company that comes up with a more effective technology in support of this stands to realize almost unlimited revenue potential in as much as it can be applied to multiple drug applications, opening the door to continued profitable growth. The road to final acceptance, of course, can be long and hard, requiring extensive up-front investment to develop and finally release a new delivery candidate.
Emisphere Technologies (OTCBB: EMIS) is a New Jersey based biopharmaceutical company that has already taken those critical first steps. It has come up with a new technology for drug delivery, and is now developing the novel products based on it to move into the marketplace. The company has a broad-based proprietary drug delivery platform called the Eligen® Technology, which improves the body’s ability to absorb select molecules. The approach provides a demonstrated safe method of transporting targeted molecules to where they are needed, while in no way affecting their biological benefit. Many of these molecules are currently injected, which can limit their beneficial effect due to poor bioavailability, slow onset of action, or inconsistent absorption. The Eligen Technology overcomes these problems, while offering a variety of delivery pathways.
The net result of the new approach is the enhancement of overall healthcare, including patient accessibility and compliance, while also benefitting the commercial pharmaceutical marketplace. One of Emisphere’s core business strategies is to use this proprietary technology to develop new oral forms of injectable drugs or poorly absorbed compounds. The broadly applicable Eligen Technology, together with Emisphere’s current product candidates in the pipeline, represent the foundation of its value proposition and a significant opportunity for growth. Emisphere’s pipeline includes product candidates that have reached clinical development, plus a variety of preclinical research and development programs.
Emisphere is carrying out these programs independently, as well as in collaboration with pharmaceutical and biotechnology companies. Promising marquee products in the pipeline include an improved formulation of oral Vitamin B12, oral calcitonin for osteoarthritis and osteoporosis (in Phase III development with Novartis), and oral GLP-1 and GLP-1 analogs for Type 2 diabetes. They are individual products representing the tip of what could be a very large iceberg, and a good reason for taking a close look at Emisphere Technologies.
For additional information, visit the company website at www.Emisphere.com.
Let us hear your thoughts below:
